4D Molecular Therapeutics, Inc. (FDMT)
- Previous Close
25.58 - Open
25.18 - Bid 25.51 x 100
- Ask 25.70 x 200
- Day's Range
24.77 - 26.07 - 52 Week Range
9.44 - 36.25 - Volume
519,424 - Avg. Volume
635,166 - Market Cap (intraday)
1.326B - Beta (5Y Monthly) 2.93
- PE Ratio (TTM)
-- - EPS (TTM)
-2.36 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
52.30
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
www.4dmoleculartherapeutics.comRecent News: FDMT
Performance Overview: FDMT
Trailing total returns as of 5/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FDMT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FDMT
Valuation Measures
Market Cap
1.33B
Enterprise Value
813.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
54.24
Price/Book (mrq)
2.21
Enterprise Value/Revenue
39.80
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.29%
Return on Equity (ttm)
-25.53%
Revenue (ttm)
20.45M
Net Income Avi to Common (ttm)
-104.56M
Diluted EPS (ttm)
-2.36
Balance Sheet and Cash Flow
Total Cash (mrq)
525.91M
Total Debt/Equity (mrq)
2.36%
Levered Free Cash Flow (ttm)
-49.05M
Research Analysis: FDMT
Company Insights: FDMT
FDMT does not have Company Insights